[{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"6abdabcb-20ec-463a-9da6-da3f3fef4258","acronym":"","url":"https://clinicaltrials.gov/study/NCT03502330","created_at":"2021-01-18T17:14:06.052Z","updated_at":"2025-02-25T14:26:50.517Z","phase":"Phase 1","brief_title":"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma","source_id_and_acronym":"NCT03502330","lead_sponsor":"Yale University","biomarkers":" PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227) • sotigalimab (PYX-107)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/09/2018","start_date":" 06/09/2018","primary_txt":" Primary completion: 01/05/2022","primary_completion_date":" 01/05/2022","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-07-03"},{"id":"847c8261-9d7c-4c47-a268-27585ac7ebd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02600949","created_at":"2021-01-18T12:37:39.802Z","updated_at":"2024-07-02T16:34:26.760Z","phase":"Phase 1","brief_title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","source_id_and_acronym":"NCT02600949","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-12"},{"id":"9ce2998a-b97d-42c7-814f-e91e27b1b1ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03719430","created_at":"2024-02-02T19:19:38.476Z","updated_at":"2024-07-02T16:35:15.675Z","phase":"Phase 2","brief_title":"APX005M and Doxorubicin in Advanced Sarcoma","source_id_and_acronym":"NCT03719430","lead_sponsor":"Alexander Z. Wei, MD","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-08"},{"id":"21f257bd-30a7-4fd4-8bc4-d36716f22498","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123783","created_at":"2021-01-18T15:23:33.485Z","updated_at":"2025-02-25T14:37:31.643Z","phase":"Phase 1/2","brief_title":"CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab","source_id_and_acronym":"NCT03123783","lead_sponsor":"Apexigen America, Inc.","biomarkers":" EGFR • BRAF • ALK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation","tags":["EGFR • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sotigalimab (PYX-107)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 07/10/2017","start_date":" 07/10/2017","primary_txt":" Primary completion: 11/16/2020","primary_completion_date":" 11/16/2020","study_txt":" Completion: 11/16/2020","study_completion_date":" 11/16/2020","last_update_posted":"2023-12-25"},{"id":"1b7b4334-9e53-4fce-8f9f-0c4969bb2c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT02482168","created_at":"2021-01-18T11:57:11.381Z","updated_at":"2024-07-02T16:35:25.663Z","phase":"Phase 1","brief_title":"Study of the CD40 Agonistic Monoclonal Antibody APX005M","source_id_and_acronym":"NCT02482168","lead_sponsor":"Apexigen America, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 06/13/2018","primary_completion_date":" 06/13/2018","study_txt":" Completion: 06/19/2018","study_completion_date":" 06/19/2018","last_update_posted":"2023-12-20"}]